BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Earnings Recaps

BCRX Health Care 3 recaps
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 7, 2026

BioCryst shares fell 3.9% after earnings, with the likely concern that the quarter’s revenue included an upper-teens-of-millions contribution from CareMed’s one-time inventory build, making reported growth less representative of underlying demand. The company said ORLADEYO revenue excluding Europe still grew year over year after removing that benefit, but future revenue should more closely reflect patient demand.

Key takeaways
  • Net revenue was $174.8 million in the quarter, with more than 95% from the U.S. business.
  • ORLADEYO revenue excluding Europe increased 20% year over year on a comparable basis; the CareMed inventory build contributed an upper-teens-of-millions amount to quarterly revenue.
  • CareMed’s inventory is expected to remain near the lower end of its typical 1-to-3-week range, limiting that transition-related revenue contribution going forward. BioCryst said days to first shipment for new patients are already improving.
  • Management reported continued growth in treated patients and new prescribers, and said early uptake of ORLADEYO pellets in children has been promising.
  • Navenibart’s pivotal trial fully enrolled in June, with 12-month top-line data still expected in the third quarter of next year; early BCX1777 data are expected by year-end.
Q2 2026 Aug 7, 2026

BioCryst’s shares gained 3.1% following Q2 results highlighted by solid ORLADEYO revenue growth and successful pediatric launch execution, reflecting confidence in commercial momentum and operational progress.

Key takeaways
  • Total revenue rose 45% year-over-year on a comparable basis, excluding the European divestiture.
  • ORLADEYO revenue increased 10% year-over-year to $158.2 million, supported by strong new patient demand and steady new prescriber additions.
  • Pediatric ORLADEYO pellets launched with 47 prescriptions received through July 31, exceeding full-year expectations despite earlier manufacturing delays.
  • Paid prescription rate improved slightly to 84%, up from 83% a year ago, following completion of a major reauthorization season.
  • Strategic shift to end internal drug discovery to focus on external innovation aims to build a more balanced pipeline without impacting current clinical programs.
Q3 2025 Nov 5, 2025

BioCryst reported a robust Q3 2025, driven by strong revenue growth for ORLADEYO, strategic divestitures, and a clean balance sheet, setting the stage for future expansion.

Key takeaways
  • ORLADEYO revenue guidance raised to $590-$600 million for 2025, even amid increased competition.
  • Successful divestiture of European operations and debt payoff, resulting in an operating profit and positive cash flow.
  • Encouraging early data expected from the BCX17725 study for Netherton syndrome, with patient enrollment slightly delayed.
  • Anticipating the acquisition of Astria to enhance the pipeline with navenibart, targeting expanded HAE treatment options.
  • New prescriptions for ORLADEYO exceeded prior year totals, reflecting continued strong market demand and physician trust.